EPIRUBICIN HYDROCHLORIDE INJECTION SOLUTION

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

EPIRUBICIN HYDROCHLORIDE

थमां उपलब्ध:

STRIDES PHARMA CANADA INC

ए.टी.सी कोड:

L01DB03

INN (इंटरनेशनल नाम):

EPIRUBICIN

डोज़:

2MG

फार्मास्यूटिकल फॉर्म:

SOLUTION

रचना:

EPIRUBICIN HYDROCHLORIDE 2MG

प्रशासन का मार्ग:

INTRAVENOUS

पैकेज में यूनिट:

25/100ML

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

ANTINEOPLASTIC AGENTS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0116901002; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2020-05-19

उत्पाद विशेषताएं

                                IMPORTANT: PLEAS
_EPIRUBICIN HYDROCHLORIDE INJECTION PRODUCT MONOGRAPH _
_ _
_PAGE 1 OF 40_
PRODUCT
MONOGRAPH
PR
EPIRUBICIN HYDROCHLORIDE
INJECTION
2 mg/mL
STERILE SOLUTION FOR INTRAVENOUS USE
ANTINEOPLASTIC AGENT
Strides Pharma Canada Inc.
1565, Boul. Lionel-Boulet,
Varennes, QC J3X 1P7
Canada
Date of Revision:
April 18, 2023
Submission Control No.: 269680
IMPORTANT: PLEAS
_EPIRUBICIN HYDROCHLORIDE INJECTION PRODUCT MONOGRAPH _
_ _
_PAGE 2 OF 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
.....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
4
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
5
ADVERSE REACTIONS
..............................................................................................................
11
DRUG INTERACTIONS
...............................................................................................................
14
DOSAGE AND ADMINISTRATION
...........................................................................................
15
OVERDOSAGE
.............................................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
18
STORAGE AND STABILITY
......................................................................................................
20
SPECIAL HANDLING INSTRUCTIONS
....................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
..........................................................
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 14-05-2020

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें